Trump signs executive order to research ibogaine, a psychedelic used abroad to treat PTSD
perigon
Last updated: April 19, 2026
President Trump has signed an executive order aimed at easing restrictions on the psychedelic ibogaine. This move signifies a potential shift in U.S. policy, opening doors for increased research into the drug's therapeutic applications. The order signals the administration's willingness to explore the potential benefits of ibogaine.
- President Trump's executive order facilitates the easing of regulations surrounding ibogaine, a naturally occurring psychedelic compound.
- This action indicates a governmental openness to expanding scientific investigation into ibogaine's properties and potential uses.
- Ibogaine is recognized for its psychoactive effects and has been explored for its therapeutic potential.
- The executive order suggests a move towards encouraging more in-depth studies within the United States.
- This development could pave the way for a broader understanding of ibogaine's effects on mental health conditions.
- The administration's decision highlights a willingness to reconsider existing policies on certain psychoactive substances for research purposes.
- This could lead to clinical trials and further exploration of ibogaine-assisted therapy.
- The focus is on scientific research rather than recreational use.
- The order implies a procedural simplification for researchers wishing to study ibogaine.
- This could accelerate the discovery of new treatments.
- The exact scope and implementation details of the eased restrictions are subject to further clarification.
- The order emphasizes a research-oriented approach.
- This is a notable policy shift regarding psychedelics in a medical research context.
